Clinical Trials Insight: 700036982

Trial Profile

Clinical Trials Insight: 700036982

Completed
Phase of Trial: Phase I

Latest Information Update: 12 May 2009

At a glance

  • Drugs PSN 821 (Primary)
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Most Recent Events

    • 12 May 2009 Results reported in an OSI Pharmaceuticals media release. Results are also expected to be presented together with the second phase I trial (trial profile 700044736) at a scientific session.
    • 12 May 2009 According to an OSI Pharmaceuticals media release, data from this trial was used to support progression of PSN821 into a 14-day trial (see trial profile 700044736).
    • 12 May 2009 Status changed from recruiting to completed, according to an OSI Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top